Biological evaluation of Tc-99m-labeled cyclic glycoprotein IIb/IIIa receptor antagonists in the canine arteriovenous shunt and deep vein thrombosis models: Effects of chelators on biological properties of [Tc-99m]chelator-peptide conjugates

被引:50
作者
Barrett, JA
Damphousse, DJ
Heminway, SJ
Liu, S
Edwards, DS
Looby, RJ
Carroll, TR
机构
[1] Radiopharmaceuticals Division, Dupont Merck Pharmaceutical Company, North Billerica, MA 01862
关键词
D O I
10.1021/bc9500960
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A series of Tc-99m-labeled cyclic glycoprotein IIb/IIIa receptor antagonists, [(TcO)-Tc-99m(L1-III)](-), [(TcO)-Tc-99m(L6-III)](-), [(TcO)-Tc-99m(L1-V)](-), and [(TcO)-Tc-99m(L6-V)](-), were evaluated in a canine arteriovenous (AV) shunt model for their potential use as thrombus imaging agents. The thrombus formed consists of a platelet-rich head and a fibrin-rich tail. All four agents were incorporated into the growing thrombus under both arterial (platelet-rich) and venous (platelet-poor) conditions. The rank order for uptake was [(TcO)-Tc-99m(L1-V)](-) > [(TcO)-Tc-99m(L6-V)](-) > [(TcO)-Tc-99m(L6-III)](-) > [(TcO)-Tc-99m(L1-III)](-) (arterial range, 5.8-0.47 % id/g; venous range, 0.58-0.04 % id/g). The uptakes of both [(TcO)-Tc-99m(L6-III)](-) and [(TcO)-Tc-99m(L1-III)](-) under both arterial and venous conditions were not significantly greater than that of [Tc-99m]-albumin and [I-125]fibrinogen In-contrast, the uptakes of both [(TcO)-Tc-99m(L1-V)](-) and [(TcO)-Tc-99m(L6-V)](-) were significantly greater than those of [Tc-99m]albumin and [I-125]fibrinogen and comparable to that of [In-111]platelets under both arterial and venous conditions. All four [Tc-99m]chelator-peptide conjugates are cleared faster than the controls with the clearance of the conjugates of peptide III faster than that of the conjugates of peptide V. The differences in incorporation are attributable to the effect of both the cyclic peptide and the chelator. The conjugate [(TcO)-Tc-99m(L1-V)](-) was also studied using a canine DVT (deep vein thrombosis) model. [(TcO)-Tc-99m(L1-V)](-) was actively incorporated into the growing thrombus with images clearly detectable within 15 min postinjection. At 2 h postinjection, thrombus/blood and thrombus/muscle ratios [region of interest (ROI)/background] were approximately 7/1 and 10/1, respectively. This clearly demonstrated that the conjugate [(TcO)-Tc-99m(L1-V)](-) has the potential for rapid diagnosis of thrombolic events occurring under both arterial and venous conditions.
引用
收藏
页码:203 / 208
页数:6
相关论文
共 11 条
  • [1] ANTITHROMBOTIC THERAPY AFTER MYOCARDIAL REPERFUSION IN ACUTE MYOCARDIAL-INFARCTION
    FUSTER, V
    STEIN, B
    BADIMON, L
    CHESEBRO, JH
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1988, 12 (06) : A78 - A84
  • [2] PREVENTION OF REOCCLUDING PLATELET-RICH THROMBI IN CANINE FEMORAL ARTERIES WITH A NOVEL PEPTIDE ANTAGONIST OF PLATELET GLYCOPROTEIN-IIB-IIIA RECEPTORS
    HASKEL, EJ
    ADAMS, SP
    FEIGEN, LP
    SAFFITZ, JE
    GORCZYNSKI, RJ
    SOBEL, BE
    ABENDSCHEIN, DR
    [J]. CIRCULATION, 1989, 80 (06) : 1775 - 1782
  • [3] RADIOPHARMACEUTICALS FOR THROMBUS DETECTION
    KNIGHT, LC
    [J]. SEMINARS IN NUCLEAR MEDICINE, 1990, 20 (01) : 52 - 67
  • [4] KNIGHT LC, 1993, J NUCL MED, V34, pP66
  • [5] KNIGHT LC, 1993, J NUCL MED, V34, pP17
  • [6] Labeling cyclic glycoprotein IIb/IIIa receptor antagonists with Tc-99m by the preformed chelate approach: Effects of chelators on properties of [Tc-99m]chelator-peptide conjugates
    Liu, S
    Edwards, DS
    Looby, RJ
    Poirier, MJ
    Rajopadhye, M
    Bourque, JP
    Carroll, TR
    [J]. BIOCONJUGATE CHEMISTRY, 1996, 7 (02) : 196 - 202
  • [7] THROMBUS RADIOIMMUNOSCINTIGRAPHY - AN APPROACH USING MONOCLONAL ANTIPLATELET ANTIBODY
    OSTER, ZH
    SRIVASTAVA, SC
    SOM, P
    MEINKEN, GE
    SCUDDER, LE
    YAMAMOTO, K
    ATKINS, HL
    BRILL, AB
    COLLER, BS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (10) : 3465 - 3468
  • [8] FIBRINOGEN, FIBRINOGEN RECEPTORS, AND THE PEPTIDES THAT INHIBIT THESE INTERACTIONS
    PLOW, EF
    MARGUERIE, G
    GINSBERG, M
    [J]. BIOCHEMICAL PHARMACOLOGY, 1987, 36 (23) : 4035 - 4040
  • [9] RAJOPADHYE M, UNPUB
  • [10] SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107